Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 135M | 3.4% |
| Gross Profit | 135M | 3.4% |
| Cost of Revenue | 130,000 | 1.6% |
| Operating expense | 490,000 | 643.3% |
| Net Income | 12M | 30% |
| EBITDA | 20M | 23.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 600M | 0.4% |
| Total Liabilities | 350M | 2.2% |
| Total Equity | 251M | 4.4% |
| Shares Outstanding | 47M | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 13M | 23.6% |
| Cash from investing | -490,000 | 28.5% |
| Cash from financing | -8.8M | 35.5% |
EPS
Financial Highlights for Core Laboratories in Q3 '24
Core Laboratories reported a revenue of 135M, which is a 3.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 135M, marking a 3.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 130,000, a -1.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 490,000, showing a 643.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 12M, showing a 30% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 20M, showing a 23.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Core Laboratories with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
